556 related articles for article (PubMed ID: 26172084)
41. Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
Yamada Y; Senda M; Naito Y; Tamura M; Watanabe D; Shuto Y; Urita Y
Diabetes Obes Metab; 2017 Sep; 19(9):1252-1259. PubMed ID: 28345162
[TBL] [Abstract][Full Text] [Related]
42. Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial.
Bolli GB; Landgraf W; Bosnyak Z; Melas-Melt L; Home PD
Diabetes Obes Metab; 2020 Sep; 22(9):1664-1669. PubMed ID: 32314521
[TBL] [Abstract][Full Text] [Related]
43. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
[TBL] [Abstract][Full Text] [Related]
44. A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen.
Bolli GB; Wysham C; Fisher M; Chevalier S; Cali AMG; Leroy B; Riddle MC
Diabetes Obes Metab; 2019 Feb; 21(2):402-407. PubMed ID: 30160030
[TBL] [Abstract][Full Text] [Related]
45. Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL.
Landgraf W; Owens DR; Frier BM; Zhang M; Bolli GB
Diabetes Obes Metab; 2020 Mar; 22(3):315-323. PubMed ID: 31608548
[TBL] [Abstract][Full Text] [Related]
46. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
Sullivan SD; Bailey TS; Roussel R; Zhou FL; Bosnyak Z; Preblick R; Westerbacka J; Gupta RA; Blonde L
Diabetes Obes Metab; 2018 Sep; 20(9):2148-2158. PubMed ID: 29938887
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study.
Blevins TC; Barve A; Sun B; Ankersen M
Diabetes Obes Metab; 2018 Aug; 20(8):1944-1950. PubMed ID: 29656504
[TBL] [Abstract][Full Text] [Related]
48. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Tuttle KR; Lakshmanan MC; Rayner B; Busch RS; Zimmermann AG; Woodward DB; Botros FT
Lancet Diabetes Endocrinol; 2018 Aug; 6(8):605-617. PubMed ID: 29910024
[TBL] [Abstract][Full Text] [Related]
49. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
Hollander P; Sugimoto D; Vlajnic A; Kilo C
J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
Yang W; Dong X; Li Q; Cheng Z; Yuan G; Liu M; Xiao J; Gu S; Niemoeller E; Chen L; Ping L; Souhami E;
Diabetes Obes Metab; 2022 Aug; 24(8):1522-1533. PubMed ID: 35441412
[TBL] [Abstract][Full Text] [Related]
51. Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment.
Javier Escalada F; Halimi S; Senior PA; Bonnemaire M; Cali AMG; Melas-Melt L; Karalliedde J; Ritzel RA
Diabetes Obes Metab; 2018 Dec; 20(12):2860-2868. PubMed ID: 30003642
[TBL] [Abstract][Full Text] [Related]
52. Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trial.
Yuan X; Guo X; Zhang J; Dong X; Lu Y; Pang W; Gu S; Niemoeller E; Ping L; Nian G; Souhami E;
Diabetes Obes Metab; 2022 Nov; 24(11):2182-2191. PubMed ID: 35762489
[TBL] [Abstract][Full Text] [Related]
53. Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.
Owens DR; Bolli GB; Charbonnel B; Haak T; Landgraf W; Porcellati F; Traylor L; Kautzky-Willer A
Diabetes Obes Metab; 2017 Nov; 19(11):1546-1554. PubMed ID: 28449412
[TBL] [Abstract][Full Text] [Related]
54. Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study.
Cheng A; Harris S; Giorgino F; Seufert J; Ritzel R; Khunti K; Lauand F; Melas-Melt L; Westerbacka J; Bosnyak Z; Rosenstock J
Diabetes Obes Metab; 2020 Mar; 22(3):346-354. PubMed ID: 31646724
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.
Hollander PA; Carofano WL; Lam RLH; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rendell MS; Home PD; Gallwitz B; Rosenstock J
Diabetes Obes Metab; 2018 Sep; 20(9):2229-2237. PubMed ID: 29761615
[TBL] [Abstract][Full Text] [Related]
56. Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus.
Freemantle N; Mauricio D; Giaccari A; Bailey T; Roussel R; Franco D; Berthou B; Pilorget V; Westerbacka J; Bosnyak Z; Bonnemaire M; Cali AMG; Nguyên-Pascal ML; Penfornis A; Perez-Maraver M; Seufert J; Sullivan SD; Wilding J; Wysham C; Davies M
Curr Med Res Opin; 2020 Apr; 36(4):571-581. PubMed ID: 31865758
[No Abstract] [Full Text] [Related]
57. Switching the basal insulin to insulin glargine 300 U/ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety.
Seufert J; Wiesli P; Fritsche A; Anderten H; Pegelow K; Pscherer S; Pfohl M
Diabetes Obes Metab; 2022 Jan; 24(1):72-81. PubMed ID: 34514696
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
[TBL] [Abstract][Full Text] [Related]
59. Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study.
Malik RA; Hwu CM; Jammah AA; Arteaga-Díaz JM; Djaballah K; Pilorget V; Alvarez A; Vera C; Vikulova O
Diabetes Obes Metab; 2024 Jul; 26(7):2811-2819. PubMed ID: 38637981
[TBL] [Abstract][Full Text] [Related]
60. Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial.
Davies MJ; Russell-Jones D; Selam JL; Bailey TS; Kerényi Z; Luo J; Bue-Valleskey J; Iványi T; Hartman ML; Jacobson JG; Jacober SJ;
Diabetes Obes Metab; 2016 Nov; 18(11):1055-1064. PubMed ID: 27349219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]